Mallinckrodt Pharma acquires Therakos for USD 1.3 billion from Gores Group

August 12, 2015

Mallinckrodt, a leader in biopharmaceutical has signed an agreement to buy a leading immunotherapy company Therakos Inc, from the global investment firm, Gores Group for approximately 1.325 billion US dollars.
Significance of Therakos Acquisition:

Therakos Inc is a US based global leader in autologous immune cell therapy delivered through extracorporeal photopheresis (ECP) that focuses to harness the power of patients’ immune systems to fight blood cancer.
Its latest generation Cellex Photopheresis System is the only approved fully integrated systems in the world for administering autologous immune cell therapy through ECP.
Therakos Photopheresis specifically deals with the treatment of a blood cancer that affects the skin for patients who have not been responsive to other forms of treatment.
This therapeutic platforms of Therakos is used by hospitals, academic medical centres and treatment centres in more than 25 countries and deliver over one million photopheresis treatments globally.
Mallinckrodt a Dublin, Ireland based drug and medical device maker expects to broaden its specialty segment in hospitals through innovative therapies and devices of Therakos.
Mallinckrodt with this acquisition want to enlarge its presence into immunotherapy, pain management, critical-care respiratory therapies in neonatal intensive care units that has strong foot prints in nuclear medicines.

Autologous immune cell therapy: It is a therapy in which immune cells of the cancer patient is taken out of his/her body which are cultured and processed to activate them for resistance to cancer is strengthened and then the cells are put back in the body.

« Previous Post Next Post »